TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 110, Issue 40, Pages 16127-16132
Publisher
Proceedings of the National Academy of Sciences
Online
2013-09-17
DOI
10.1073/pnas.1311055110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
- (2013) Austin G. Kulasekararaj et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts
- (2012) B H Yip et al. LEUKEMIA
- New therapeutics for myelodysplastic syndromes
- (2012) Alan F. List LEUKEMIA RESEARCH
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
- (2012) S Wei et al. ONCOGENE
- Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
- (2011) A. Narla et al. BLOOD
- Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
- (2011) Jorge Cortes et al. CANCER
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia
- (2011) Mark C. Lanasa et al. LEUKEMIA & LYMPHOMA
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
- (2010) C. Frank Bennett et al. Annual Review of Pharmacology and Toxicology
- Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells
- (2010) S. Dutt et al. BLOOD
- New insights into 5q- syndrome as a ribosomopathy
- (2010) Jillian L. Barlow et al. CELL CYCLE
- A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice
- (2010) Katerina I. Leonova et al. CELL CYCLE
- GATA-1 associates with and inhibits p53
- (2009) C. D. Trainor et al. BLOOD
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
- (2009) S. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myelodysplastic syndromes
- (2008) S. D. Nimer BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now